FLT3 and acute myeloid leukemia: Moreover, in AML with FLT3 internal tandem duplication (FLT3 ITD) inhibitors of FLT3, sorafenib, midostaurin, quizartinib, gilteritinib, and others, are also intensively assessed in active phase II–III trials [72].